Abstract: Described are methods, devices, and systems related to implants for the treatment of a female pelvic condition. The implants include absorbable and non-absorbable materials and can be introduced into the pelvic area transvaginally. Meshes of the invention provide benefits relating to improved tissue integration into the mesh, reduced infection likelihood, improved patient comfort following implantation, or combinations of thereof.

Abstract: Implant systems and methods are provided to include a treatment material with a pelvic implant device. The pelvic implant device, such as an incontinence sling, can include the treatment coating combination of a material, such as Phosphorylcholine (PC), and an infection prevention material, such as InhibiZone® (IZ) technology. The treatment material can be coated onto, or impregnation or integrated with, polypropylene mesh in order to prevent infection and promote healing.

Abstract: Various embodiments of a mesh or implant system are provided for treating pelvic conditions such as incontinence, vaginal prolapsed, and other conditions caused by muscle and ligament weakness. Embodiments of the implants can include a material, substrate, configuration or coating adapted to provide immediate or timed release of various therapeutic agents or drugs to treat the surrounding tissue.

Abstract: A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent. The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.

Abstract: A method for treating proliferative diseases by delivering a combination of at least two pharmaceutically active agents to a diseased area or tissue comprising a coating layer of two hydrophobic drugs applied to an exterior surface of a device or a substrate wherein the first pharmaceutically active agent is selected from a group consisting of mTor inhibitors and the second pharmaceutically active agent is selected from a group of consisting of NF-k? inhibitors. Further a method for treating proliferative diseases by delivering a combination of at least two pharmaceutically active agents to a diseased area or tissue comprising: a coating layer of two hydrophobic drugs applied to an exterior surface of a medical device or substrate and a polymer blend carrier for the pharmaceutically active agents.

Abstract: The methods using associated formulations for intra-articular local delivery to treat an afflicted joint, for example, to treat osteoarthritis. Some methods deliver anti-inflammatory agents and angiogenesis inhibitors, and can include sensitizing agents for one or both. Formulations can include hyaluronic acid, a therapeutic solvent, and drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The carrier can include hydrophobic sugar nano-particles, which can resist degradation and provide extended cushioning. The excipient or polymer can be used to manipulate release rates and to increase drug retention to the affected region.

Abstract: Described are methods, devices, and systems related to implants for the treatment of a female pelvic condition. The implants include absorbable and non-absorbable materials and can be introduced into the pelvic area transvaginally. Meshes of the invention provide benefits relating to improved tissue integration into the mesh, reduced infection likelihood, improved patient comfort following implantation, or combinations of thereof.

Abstract: Described are methods, devices, and systems related to implants for the treatment of a female pelvic condition. The implants include absorbable and non-absorbable materials and can be introduced into the pelvic area transvaginally. Meshes of the invention provide benefits relating to improved tissue integration into the mesh, reduced infection likelihood, improved patient comfort following implantation, or combinations of thereof.

Abstract: Various embodiments of a pharmaceutical composition for closing or sealing an opening or a bleeding site such as a vascular puncture site following percutaneous diagnostic or therapeutic interventional procedures or any other non-vascular conduits such fistulas formed within the organs of the body. The injectable composition includes a formulation comprised of a hemostatic compound and a bioadhesive that can be injected at a positioned adjacent to the puncture site in the vasculature, or injected into the non-vascular lumen to fill the conduit created at the puncture site. In some embodiments, the formulation also contains an analgesic agent to reduce pain at the puncture site and provide comfort to the patient. In other embodiments, the formulation contains a pro-healing agent to promote the healing process of the puncture site or the non-vascular conduit.

Abstract: A balloon catheter for delivering a combination of pharmaceutical active agents to a diseased blood vessel or conduit comprising an exterior coating layer of hydrophobic drugs with a first therapeutic agent is an mTor inhibitor and a second is an NF-k? inhibitor. The pharmaceutical composition for treating proliferative diseases is further comprised of a mixture of two hydrophobic therapeutic agents coated on a medical device, with a first therapeutic agent is an mTor inhibitor and the second therapeutic agent is an NF-k? inhibitor. The device and pharmaceutical combination comprise a method for treating proliferative diseases.

Abstract: A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent, The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.

Abstract: A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent. The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.

Abstract: Various embodiments of a mesh or implant system are provided for treating pelvic conditions such as incontinence, vaginal prolapsed, and other conditions caused by muscle and ligament weakness. Embodiments of the implants can include a material, substrate, configuration or coating adapted to provide immediate or timed release of various therapeutic agents or drugs to treat the surrounding tissue.

Abstract: A uterine fibroid treatment device providing for localized delivery of one or more treatment drugs for treating various uterine conditions including, for example, uterine fibroids, abnormal uterine bleeding, pelvic adhesions and endometriosis. Generally, the uterine treatment device comprises a physical positioning element that can be inserted, positioned and maintained in close proximity to the uterine tissue to be treated. The treatment drugs delivered to the treatment location can include various combinations of anti-proliferative agents and angiogenesis inhibitors to provide different treatments concurrently. In some embodiments, the physical element can also serve the dual purpose of delivering the treatment drugs while simultaneously cutting off blood flow to a mature fibroid to initiate hypoxic/ischemic conditions within the mature fibroid.

Abstract: Described are methods, devices, and systems related to implants for the treatment of a female pelvic condition. The implants include absorbable and non-absorbable materials and can be introduced into the pelvic area transvaginally. Meshes of the invention provide benefits relating to improved tissue integration into the mesh, reduced infection likelihood, improved patient comfort following implantation, or combinations of thereof.

Abstract: Various embodiments of a fibroid treatment system and method are provided. Embodiments are adapted to treat fibroids utilizing by blocking or impeding blood flow through the uterine artery to prevent growth of the fibroid. Additionally, drugs or therapeutic agents can be included to further shrink or starve off the fibroid to provide a secondary mode of action.

Abstract: Implant systems and methods are provided to include a treatment material with a pelvic implant device. The pelvic implant device, such as an incontinence sling, can include the treatment coating combination of a material, such as Phosphorylcholine (PC), and an infection prevention material, such as InhibiZone® (IZ) technology. The treatment material can be coated onto, or impregnation or integrated with, polypropylene mesh in order to prevent infection and promote healing.

Abstract: A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent. The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.

Abstract: Implant systems and methods are provided to include a treatment material with a pelvic implant device. The pelvic implant device, such as an incontinence sling, can include the treatment coating combination of polycarbonate (PC) and an infection prevention material, such as InhibiZone® (IZ) technology. The treatment material can be coated onto, or impregnation or integrated with, polypropylene mesh in order to prevent infection and promote healing.

Abstract: The present invention provides a medical device, and methods of preparing and using a medical device. The medical device has a surface including a biologically active agent therein. The methods are particularly useful for preparing, for example, coated stents having a biologically active agent within the coating.